No black box warning on record for Invega Sustenna

As of the latest FDA labeling reviewed, Invega Sustenna (PALIPERIDONE PALMITATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Invega Sustenna medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack). ( 5.2 ) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of drug and close monitoring. ( 5.3 ) QT Prolongation: Avoid use with drugs that also incr

No black box warning on record for Invega Sustenna

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack). ( 5.2 ) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of drug and close monitoring. ( 5.3 ) QT Prolongation: Avoid use with drugs that also incr

Invega Sustenna Black Box Warning

No black box warning on record for Invega Sustenna

Other warnings & precautions

Invega Sustenna Black Box Warning

No black box warning on record for Invega Sustenna

Other warnings & precautions